Clearer survival measures for cancer treatment decisions
Survival Data Analysis using general censoring-free incident rate
A new statistical approach to give patients and doctors clearer numbers about how cancer treatments change survival over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11309126 on NIH RePORTER |
What this research studies
From my perspective as a patient, the team is creating a new summary measure called the "average hazard" to make survival results easier to understand. They will develop the mathematics and test the method using clinical trial data and simulations to compare it with standard hazard-ratio and log-rank approaches. The work focuses on producing censoring-free person-time incidence rates that aim to show the magnitude of benefit or risk more directly. If adopted, the method could make trial results more useful when choosing between cancer treatments.
Who could benefit from this research
Good fit: Patients with cancer who are enrolled in clinical trials that record time-to-event outcomes (like survival or progression) or who can provide access to their trial data are most relevant.
Not a fit: People not enrolled in trials or whose care does not involve time-to-event outcomes would likely not see direct benefit from this work.
Why it matters
Potential benefit: This could give patients and clinicians more directly interpretable numbers about treatment risks and benefits, improving shared decision-making.
How similar studies have performed: Traditional tools like hazard ratios and log-rank tests are well established but sometimes hard to interpret, and this "average hazard" approach is novel and not yet widely used in practice.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Uno, Hajime — Dana-Farber Cancer Inst
- Study coordinator: Uno, Hajime
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.